Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2808 Target Snapshot

Oxysterols receptor LXR-alpha · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,773Compounds
457Assays
2Approved Drugs
2,197.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Oxysterols receptor LXR-alpha shows clinical signal disease relevance led by Hypercholesterolemia. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q13133. Start with Hypercholesterolemia, then reuse UniProt Q13133 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Hypercholesterolemia, then reuse UniProt Q13133 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
Hypercholesterolemia

Oxysterols receptor LXR-alpha shows clinical signal disease relevance led by Hypercholesterolemia. 2 linked drugs remain visible in the same block.

Start review with Hypercholesterolemia because it currently carries clinical signal support. Linked drugs include BMS-852927, HYODEOXYCHOLIC_ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Oxysterols receptor LXR-alpha as ChEMBL target CHEMBL2808, mapped to UniProt Q13133. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Oxysterols receptor LXR-alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2808
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13133
Oxysterols receptor LXR-alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Oxysterols receptor LXR-alpha is the right protein anchor across sources, using UniProt Q13133 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Hypercholesterolemia is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameOxysterols receptor LXR-alpha
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ13133
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelOxysterols receptor LXR-alpha
UniProt AccessionQ13133
Component TypeProtein
Sequence Length447 aa

Oxysterols receptor LXR-alpha

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Oxysterols receptor LXR-alpha, mapped to UniProt Q13133. Sequence length is 447 aa.

Mapped IDQ13133
Review nameOxysterols receptor LXR-alpha
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Oxysterols receptor LXR-alpha shows clinical signal disease relevance led by Hypercholesterolemia.

Clinical signal Phase I
Hypercholesterolemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugBMS-852927
Linked drugHYODEOXYCHOLIC_ACID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Hypercholesterolemia because it currently carries clinical signal support. Linked drugs include BMS-852927, HYODEOXYCHOLIC_ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHypercholesterolemia
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC50670.0
KI445.0
EC501,069.0
KD13.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL595012 9.1 IC50 0.8 Preclinical
CHEMBL611735 9.09 IC50 0.81 Preclinical
CHEMBL592506 9.04 IC50 0.92 Preclinical
CHEMBL555373 9.0 EC50 1.0 Preclinical
CHEMBL365544 9.0 EC50 1.0 Preclinical
CHEMBL506838 9.0 EC50 1.0 Preclinical
CHEMBL603636 9.0 IC50 1.0 Preclinical
CHEMBL595689 9.0 IC50 1.0 Preclinical
CHEMBL384246 9.0 IC50 1.0 Preclinical
CHEMBL365544 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

186
5.0
326
5.5
297
6.0
314
6.5
211
7.0
100
7.5
75
8.0
30
8.5
16
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

BEXAROTENE
CHEMBL1023
Approved 1999
Properties Compare Identifier
Assay Landscape

Assay Landscape

457
Total Assays
1,174
Tested Compounds
3
Assay Types
Binding — 359 assays, 1,174 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 223 339 6.2
single protein format 114 741 6.5
assay format 22 94 6.7
Functional — 88 assays, 194 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 56 128 5.8
assay format 32 66 6.2
ADME — 10 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 10 20 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine